Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–38 of 14 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: bexarotene Clear all
Withdrawn Not applicable Interventional

Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.

NCT05106192
View directory record Official record
Conditions
Mycosis Fungoides of Skin (Diagnosis), Cutaneous T-cell Lymphoma, Non Hodgkin Lymphoma, Lymphomatoid Papulosis, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Follicular
Interventions
Med-Jet Injector, Triamcinolone Acetonide, Bexarotene 1% Top Gel, Nitrogen Mustard, Conventional syringe
Device · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Sep 23, 2026, 8:16 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Phase II Trial to Evaluate the Efficacy of Topical Bexarotene Gel in Patients With Parapsoriasis

NCT00322296
View directory record Official record
Conditions
Parapsoriasis
Interventions
Bexarotene 1% gel
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2013 · Synced Sep 23, 2026, 8:16 PM EDT
Recruiting Phase 1 Interventional

A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides

NCT05296304
View directory record Official record
Conditions
Cutaneous T-cell Lymphoma
Interventions
Bexarotene, Total Skin Electron Beam (TSEB)
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Commack, New York • New York, New York • Rockville Centre, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 23, 2026, 8:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer

NCT03323658
View directory record Official record
Conditions
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Invasive Breast Carcinoma
Interventions
Bexarotene, Questionnaire Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Sep 23, 2026, 8:16 PM EDT
Completed Phase 2 Interventional Results available

Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma

NCT00425555
View directory record Official record
Conditions
Cutaneous T-Cell Lymphoma
Interventions
Panobinostat
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
16
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Sep 23, 2026, 8:16 PM EDT
Completed Phase 2 Interventional Results available

BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00411632
View directory record Official record
Conditions
Lung Cancer
Interventions
Bexarotene, Erlotinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Sep 23, 2026, 8:16 PM EDT
Completed Not applicable Interventional Results available

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

NCT02551718
View directory record Official record
Conditions
Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Acute Leukemia of Ambiguous Lineage
Interventions
Chemosensitivity Assay, Cytology Specimen Collection Procedure, Gene Expression Analysis, Genetic Variation Analysis, In Vitro Sensitivity-Directed Chemotherapy
Other · Genetic · Drug
Lead sponsor
University of Washington
Other
Eligibility
3 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Sep 23, 2026, 8:16 PM EDT
Not listed Phase 2 Interventional

Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma

NCT00030589
View directory record Official record
Conditions
Lymphoma
Interventions
bexarotene, methoxsalen, UV light therapy
Drug · Procedure
Lead sponsor
Millennix
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
19
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Stanford, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Sep 23, 2026, 8:16 PM EDT
Terminated Phase 2 Interventional Results available

Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma

NCT00958074
View directory record Official record
Conditions
Cutaneous T-cell Lymphoma Stage I, Cutaneous T-cell Lymphoma Stage II, Cutaneous T-cell Lymphoma Stage III, Cutaneous T-cell Lymphoma Stage IV
Interventions
vorinostat, flow cytometry, laboratory biomarker analysis
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Sep 23, 2026, 8:16 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules in Patients With Advanced Lung Cancer

NCT00153842
View directory record Official record
Conditions
Carcinoma, Non-small-cell Lung
Interventions
Bexarotene (targretin)
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Sep 23, 2026, 8:16 PM EDT
Completed Not applicable Interventional Results available

Study of Tarceva and Targretin in Stage I-II Lung Cancer

NCT00125372
View directory record Official record
Conditions
Carcinoma, Non-small-cell Lung
Interventions
erlotinib (Tarceva) and bexarotene (Targretin)
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Sep 23, 2026, 8:16 PM EDT
Completed Phase 2 Interventional Results available

Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma

NCT00255801
View directory record Official record
Conditions
Lymphoma
Interventions
Targretin® (bexarotene), pegylated liposomal doxorubicin hydrochloride
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
5
States / cities
Hackensack, New Jersey • Buffalo, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Sep 23, 2026, 8:16 PM EDT
Completed Phase 1 Interventional

Bexarotene in Preventing Breast Cancer in Women at Genetic Risk

NCT00055991
View directory record Official record
Conditions
Breast Cancer
Interventions
bexarotene
Drug
Lead sponsor
Baylor Breast Care Center
Other
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Sep 23, 2026, 8:16 PM EDT
Terminated Phase 1 Interventional

Phase I Study of CS-7017 and Bexarotene

NCT01504490
View directory record Official record
Conditions
Solid Tumors, Lymphoma, Multiple Myeloma
Interventions
CS-7017 and Bexarotene
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 13, 2017 · Synced Sep 23, 2026, 8:16 PM EDT